Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for POCI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 10.47M
December 31, 2025 -0.1582M
September 30, 2025 -0.1581M
June 30, 2025 -0.0963M
March 31, 2025 4.298M
December 31, 2024 0.3957M
September 30, 2024 0.592M
June 30, 2024 0.468M
March 31, 2024 0.2635M
December 31, 2023 -0.1363M
September 30, 2023 -0.1389M
June 30, 2023 2.944M
March 31, 2023 -0.2637M
December 31, 2022 -0.1011M
September 30, 2022 -0.1028M
June 30, 2022 -0.269M
March 31, 2022 -0.0556M
December 31, 2021 0.4152M
September 30, 2021 1.021M
June 30, 2021 -0.0092M
March 31, 2021 0.0207M
December 31, 2020 -0.021M
September 30, 2020 -0.0209M
June 30, 2020 1.028M
March 31, 2020 -0.0147M
Date Value
December 31, 2019 -0.0024M
September 30, 2019 0.0313M
June 30, 2019 0.9392M
March 31, 2019 0.0229M
December 31, 2018 1.998M
September 30, 2018 -0.0022M
June 30, 2018 -0.0022M
March 31, 2018 -0.0051M
December 31, 2017 0.0046M
September 30, 2017 0.208M
June 30, 2017 -0.0033M
March 31, 2017 -0.0036M
December 31, 2016 0.7781M
September 30, 2016 -0.0019M
June 30, 2016 -0.0021M
March 31, 2016 -0.0203M
December 31, 2015 0.6835M
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 -0.0339M
December 31, 2014 -0.0409M
September 30, 2014 0.9336M
June 30, 2014 0.05M
March 31, 2014 0.00
December 31, 2013 0.00

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
RxSight, Inc. 0.662M
Abbott Laboratories -3.518B
Align Technology, Inc. -67.45M
AngioDynamics, Inc. -0.108M
Accuray, Inc. --